Esperion appoints John Harlow as Chief Commercial Officer effective Nov 17, 2025

Esperion Therapeutics, Inc.

John Harlow appointed CCO; base salary $535,000, target bonus 45%, sign-on bonus $35,000.
Equity grants: option for 380,000 shares and 424,536 RSUs, vesting over four years.
Harlow previously CCO at Melinta Therapeutics, where revenue nearly doubled (~85% growth from 2020 to 2024).
He reports to CEO Sheldon Koenig and joins Esperion's Executive Leadership Team.
Harlow brings over 20 years of pharma commercial leadership from Melinta, Baudax Bio, Endo, Pfizer, and Novartis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.